Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Target selectivity in mRNA silencing.

N Aronin1

  • 1University of Massachusetts, Worcester, MA 1655, USA. Aronin@umassmed.edu

Gene Therapy
|March 8, 2006
PubMed
Summary

RNA interference (RNAi) shows promise for neurodegenerative diseases, but current small interfering RNA (siRNA) therapies face challenges in targeting specific disease genes. This review explores new methods to enhance siRNA selectivity and effectiveness for treating these conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Finding the striatum in sheep: use of a multi-modal guided approach for convection enhanced delivery.

Journal of Huntington's disease·2014
Same author

Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits.

Proceedings of the National Academy of Sciences of the United States of America·2007
Same author

Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.

Experimental neurology·2002
Same author

Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2001
Same author

Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis.

Proceedings of the National Academy of Sciences of the United States of America·2001
Same author

Early and progressive accumulation of reactive microglia in the Huntington disease brain.

Journal of neuropathology and experimental neurology·2001

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • RNA interference (RNAi) is a promising therapeutic strategy for neurodegenerative diseases.
  • Current small interfering RNA (siRNA) designs often fail to selectively target disease-causing mutant alleles over wild-type alleles.
  • Trinucleotide repeat expansions in diseases like Huntington's are difficult targets for conventional siRNAs.

Purpose of the Study:

  • To review recent advancements in RNA interference mechanisms.
  • To explore modifications in siRNA design that enhance selectivity, delivery, and overall performance.
  • To address the challenges of targeting specific genetic mutations in neurodegenerative diseases.

Main Methods:

  • Review of recent scientific literature on RNA interference.
  • Analysis of novel siRNA design strategies and modifications.
  • Examination of delivery systems and performance enhancements for RNAi therapeutics.

Main Results:

  • Emerging RNAi mechanisms offer improved potential for gene silencing.
  • siRNA modifications are being developed to achieve allele-specific silencing.
  • Enhanced delivery methods are crucial for effective RNAi therapy in the central nervous system.

Conclusions:

  • Overcoming the limitations of conventional siRNA is critical for successful RNAi-based therapies.
  • Targeted modifications and improved delivery systems are key to harnessing the potential of RNAi for neurodegenerative diseases.
  • Future research should focus on developing highly selective and efficient RNAi strategies.

Related Experiment Videos